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Abstract: A set of herpes simplex virus type 1 (HSV-1) amplicon vectors expressing the light chains
(LC) of botulinum neurotoxins (BoNT) A, B, C, D, E and F was constructed. Their properties have
been assessed in primary cultures of rat embryonic dorsal root ganglia (DRG) neurons, and in
organotypic cultures of explanted DRG from adult rats. Following infection of primary cultures of
rat embryonic DRG neurons, the different BoNT LC induced efficient cleavage of their corresponding
target Soluble N-ethylmaleimide-sensitive-factor Attachment protein Receptor (SNARE) protein
(VAMP, SNAP25, syntaxin). A similar effect was observed following infection by BoNT-A LC of
organotypic cultures of adult rat DRG. To quantify and compare the functional activities of the
different BoNT LC, the inhibition of calcitonin gene-related protein (CGRP) secretion was assessed in
DRG neurons following infection by the different vectors. All BoNT-LC were able to inhibit CGRP
secretion although to different levels. Vectors expressing BoNT-F LC displayed the highest inhibitory
activity, while those expressing BoNT-D and -E LC induced a significantly lower CGRP release
inhibition. Cleavage of SNARE proteins and inhibition of CGRP release could be detected in neuron
cultures infected at less than one transducing unit (TU) per neuron, showing the extreme efficacy of
these vectors. To our knowledge this is the first study investigating the impact of vector-expressed
transgenic BoNT LC in sensory neurons.
Keywords: HSV-1 amplicon vectors; transgenic botulinum neurotoxins; light chains; sensory neurons;
DRG; SNARE proteins
Key Contribution: HSV-1-derived nonreplicative vectors, expressing the light chains (LC) of
botulinum neurotoxins (BoNT) -A, -B, -C, -D, -E and -F, were constructed and assessed. Following
infection of embryonic and adult rat DRG sensory neurons; these vectors induced very efficient
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cleavage of the corresponding SNARE proteins and consequent inhibition of CGRP secretion.
These vectors could open new perspectives in the understanding of the basic biology of BoNT-LCs,
as well as for therapeutic development.
1. Introduction
The clostridial neurotoxin family includes tetanus toxin (TeNT), produced by Clostridium tetani,
and at least seven antigenically distinct botulinum neurotoxins (BoNTs) produced by different strains of
C. botulinum (BoNT-A to -G). These proteins, which are amongst the most potent biological neurotoxins,
are responsible for the conditions of tetanus and botulism, respectively. These diseases are a direct result
of inhibition of calcium-dependent neurotransmitter release, a mechanism of action common to all
these toxins [1]. Clostridial neurotoxins are disulphide bridge-linked proteins composed of a light chain
(50 kDa), responsible for the cleavage of substrates through a zinc-dependent endoprotease activity,
and a heavy chain (100 kDa) that is involved in neurospecific binding and delivery of the neurotoxin
to the neuronal cytosol [2,3]. Once in the neuronal cytosol, the endopeptidase activity of the BoNTs
has substrate specificity for membrane-associated proteins involved in synaptic vesicle targeting,
docking, and fusion with the plasma membrane (the Soluble N-ethylmaleimide-sensitive-factor
Attachment protein Receptor, or SNARE, proteins) [4]. Each neurotoxin has distinct, unique cleavage
sites on their substrates. BoNT-A, BoNT-C and BoNT-E cleave synaptosomal-associated protein of
25 kDa (SNAP25), while BoNT-B, BoNT-D, BoNT-F and BoNT-G cleave vesicle-associated membrane
proteins (VAMP). BoNT-C is unique in having a second substrate, syntaxin (STX) [2,5,6]. Proteolytic
cleavage of any of these substrate proteins results in blockade of vesicle fusion and, in the case of
the motor end plate synapse of a motoneuron, consequent inhibition of acetylcholine release [7–9].
The inhibition of acetylcholine release from motoneurons is responsible for the pathophysiological
effects of BoNTs, leading to the impairment of striated muscle contraction. Furthermore, BoNTs
are capable of inhibiting the release of neurotransmitters from a variety of synaptosomal and
neuronal systems in vitro, including several neuroendocrine cells [10–12]. In addition to classical
small molecule neurotransmitters, such as acetylcholine and noradrenaline, BoNTs also inhibit the
release of neuropeptides, such as calcitonin gene-related peptide (CGRP) or substance P (SP) [13,14].
Studies using BoNTs have been carried out in a variety of cellular systems, including primary cultures
of murine spinal cord neurons, bovine adreno-chromaffin cells and cerebral ganglia from the sea slug
Aplysia californica. Cell lines such as the rat adrenal pheochromocytoma PC-12, 3T3-L1 adipocytes,
insulinomas HIT- 15 and RINm5F and human neuroblastoma SH-SY5Y have also been used [12,15–17].
However, in spite of these studies, many aspects of the intracellular mechanism of action of BoNTs in
neurons, and particularly in human sensory neurons, remain incompletely understood. Furthermore,
the difficulties associated with the acquisition, storage, and manipulation of these very harmful
substances, which are strictly regulated, impose considerable restrictions to their investigation.
An alternative system to the use of the whole toxins is provided by the intracellular synthesis of
the BoNTs light chains (LC) using chemical or viral vectors for gene delivery, as has been demonstrated
using adenovirus-based vectors expressing TeNT LC [18,19]. In the present study, nonreplicative,
nontoxic amplicon vectors derived from the neurotropic herpes simplex virus type 1 (HSV-1) [20,21]
were used to induce intracellular synthesis of BoNT LC, both in primary cultures of rat embryonic
dorsal root ganglia (DRG) neurons and in adult rat organotypic cultures of DRG. These vectors are fully
safe as the de novo synthesized LC cannot spread to other cells in the absence of the heavy chain [18].
Moreover, the tropism for peripheral neurons, and particularly for sensory neurons, displayed by
HSV-1 [21,22] make HSV-1-derived vectors particularly well suited for investigating the properties of
the transgenic LC in the appropriate cellular targets, while the reiterative nature of the amplicon vector
genome [20,21] produces high-level transgene expression even at very low multiplicities of infection.
Under natural in vivo conditions HSV-1 will infect mainly the oral epithelial mucosa (where the virus
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will accomplish its lytic, productive cycle) and then the sensory neurons innervating the infected area
(where the virus will stablish latent infections) [21]. However, under experimental conditions, such as
infection of cultured cells or inoculation into the stroma of specific tissues or tumors, HSV-1 vectors
can transduce and express genes in other cells types as well, including central nervous system (CNS)
neurons, sympathetic and parasympathetic neurons [23], and many non-neuronal tissues such as
muscle cells, fibroblasts, hepatocytes, pancreatic cells, and others [21,24–26].
Although BoNTs are the causative agents for clinical botulism, the potent myorelaxant properties
of these neurotoxins have been exploited clinically in many indications, including neurological and
non-neurological disorders such as cervical dystonia [27,28], blepharospasm [29,30], spasticity [31,32],
chronic migraine [33,34], idiopathic [35,36] and neurogenic detrusor overactivity [37,38], achalasia [39,
40], strabismus [41,42] and pain [43,44]. Therefore, in addition to providing a useful transducing
vehicle tool to study and compare the biochemical and molecular properties of BoNT LC using a fully
safe and powerful system, it is likely that HSV-1 vectors expressing these toxins could be used to
disrupt neurosecretion as a possible gene therapy for at least some of the above mentioned disorders,
which are generally caused by aberrant or excessive neurotransmission.
We report the construction of nonreplicative HSV-1-based amplicon vectors expressing different
BoNT LCs driven by a strong ubiquitous promoter, and show that these vectors express the transgenic
peptides in both embryonic and adult rat sensory neurons. Each transgenic BoNT LC induces cleavage
of its cognate SNARE target protein and inhibits release of neuropeptides with very high efficiency,
thus perturbing neurotransmission. Our results indicate that the different BoNT LCs display differential
efficacies in the inhibition of CGRP neurosecretion.
2. Results
2.1. Structure of the Genome of Nonreplicative HSV-1 Amplicon Vectors
We have constructed and produced a family of amplicon vectors expressing BoNT-A, -B, -C,
-D, -E and -F LC (or luciferase as a negative control), as well as an additional vector expressing a
fused GFP-BoNT-A LC. Figure 1 shows the structure of the amplicon plasmids used to generate
the corresponding amplicon vectors. Each of the vectors (except for the vector encoding the fused
GFP-BoNT-A LC cassette), expresses two independent transcription units. The first expresses the
reporter gene GFP driven by the HSV-1 immediate-early (IE) 4/5 promoter, which is useful for
measuring vector titers, to identify infected cells, and as an internal reference control for transgene
expression levels. The second transcription unit expresses one of the BoNT LC (or Luc), driven
in all cases by the immediate-early (IE) promoter of human cytomegalovirus (HCMV) to obtain
strong and ubiquitous expression. The vector expressing the green fluorescent protein (GFP)-BoNT-A
fusion protein, also driven by HCMV promoter, does not encode the IE4/5 promoter-GFP transgene
cassette. Due to the reiterative character of the amplicon genome [20,21], each vector particle carries
a concatemeric DNA consisting of multiple tandem repeats of the amplicon plasmid. All amplicon
plasmids were sequenced to confirm the accuracy of the constructions, and all of them expressed
their corresponding BoNT LC mRNA in primary cultures of rat neurons, as assessed by RT-PCR (data
not shown).
2.2. Vectors Expressing BoNT-A LC Cleave SNAP25 in Infected Neurons
The first set of experiments was designed to assess whether the amplicon vector BoNT-A LC
was able to express this protein in sensory neurons and whether the transgenic protein did induce
cleavage of its cognate SNAP25 target protein. Since there are no available commercial antibodies
recognizing any of the BoNT LC, we first used transcription cassettes in which the BoNTs LC were
labelled by a His tag. However, we were unable to detect any peptide using anti-His specific antibodies,
although this same antibody was able to recognize a His-tagged tetanus neurotoxin (TeNT, data not
shown). Therefore, we constructed a vector expressing a GFP N-terminal fusion to the BoNT-A LC
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(GFP-BoNT-A LC) to assess the presence of the fused protein in infected neurons. To this end, and
also to assess whether the fused and the non-fused BoNT-A LC proteins were able to cleave SNAP25,
primary cultures of rat embryonic DRG neurons were infected by vectors GFP-BoNT-A LC, BoNT-A
LC, or Luc (the two latter vectors also expressing GFP as a free protein) at increasing multiplicities
of infection (MOI), from 0.1 to 10.0 transducing units (TU)/neuron. At 24 h post-infection (pi) the
neuronal cultures were processed for Western blotting using antibodies specific for GFP and antibodies
that recognize both the native (about 25 kDa) and the cleaved (about 24 kDa) forms of SNAP25.
In Figure 2A, GFP is shown in green and SNAP25 is shown in red as both proteins have very similar
molecular weights. The upper panel of Figure 2A shows a dose-dependent expression of proteins
that are recognized by GFP-specific antibodies and which correspond either to the GFP-BoNT-A LC
fused protein (about 75 kDa, lanes 4–6) or to the free GFP (about 25 kDa, lanes 1–3 and 7) confirming
dose-dependent transgene expression in the infected DRG neurons. Importantly, this figure also shows
that infection with GFP-BoNT-A LC and BoNT-A LC vectors induced a dose-dependent cleavage of
SNAP25, demonstrating that both proteins are functional. Thus, at MOI of 0.1 TU/cell mostly the
native form of SNAP25 is observed (lanes 1 and 4), while at a MOI of 10 TU/cell only the cleaved form
can be observed (lanes 3 and 6). At intermediate MOI (1 TU/cell) both the native and cleaved forms
of SNAP25 can be observed (lanes 2 and 5). The negative control expressing luciferase induced no
cleavage of SNAP25 at the highest MOI (lane 7). The lower panel of this figure shows the red SNAP25
bands independently of the green bands, to facilitate detection of the SNAP25 fragments.Toxins 2019, 11, x FOR PEER REVIEW 4 of 16 
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Having demo strated that cleavage of SNAP25 was a bona fide surrogate for the expression of
BoNT-A in infected cells, we performed a further experiment in which organotypic cultures of adult
rat DRG were infected with 2 × 106 TU per explanted ganglion using vectors expressing BoNT-A LC
or Luc. Three days later, the explanted DRG cultures (three independent experiments are shown in
Figure 2B), were processed for Western blotting using antibodies that specifically recognize only the
cleaved form of SNAP25 (kindly donated by IPSEN Bioinnovation Ltd.). We used this antibody in
these tests because in the case of organotypic DRG cultures most cells would escape infection (only
the outgrowing neurites could be infected) and the presence of large amounts of noncleaved SNAP25
from noninfected cells could mask the results. As a positive control for this antibody we used rat
embryonic sensory neuron cultures infected with the BoNT-A LC vector. Figure 2B shows that a band
corresponding to the cleaved form of SNAP25 is visible in the organotypic culture of adult DRG,
thus confirming the functionality of BoNT-A LC, not only in cultured embryonic DRG neurons but
also in explanted DRG from adult animals. Altogether, these experiments clearly showed expression
and functionality of BoNT-A LC encoded by the amplicon vector, both in embryonic and adult rat
DRG neurons, thereby indicating that BoNT-A LC was able to cleave its cognate SNARE target protein
SNAP25 when intracellularly synthesized in HSV-1 amplicon vector-infected neurons.
2.3. Vectors Expressing BoNT-A LC Inhibit Secretion of CGRP Neuropeptide in Infected Neurons
Following cleavage of one or more of the SNARE proteins by BoNTs, synaptic vesicles cannot
anymore fuse with presynaptic membranes, thereby resulting in inhibition of neurosecretion and
neurotransmission. To investigate whether expression of BoNT-A LC from HSV-1 vectors in cultured
rat embryonic sensory neurons results in inhibition of neurosecretion, we assessed amounts of CGRP
in extracellular medium following vector infection. Since basal levels of CGRP secretion by sensory
neurons are low, the impact of vector infection was investigated in neurons previously treated with
KCl, which is known to induce CGRP release [45]. Primary cultures of rat embryonic sensory neurons
were infected at increasing MOI (from 0.1 to 3.0 TU/cell) with vectors expressing BoNT-A LC or
Luc. The following day, three different tests were performed: from a first group of infected neurons
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(a pool of three wells of infected cells/MOI), RNA was extracted and qRT-PCR was performed to
assess levels of BoNT-A LC RNA expression. As expected, there is a dose-dependent increase in RNA
expression following infection at increasing MOIs (Figure 3A). A second group of neurons (also a pool
of 3 wells/MOI) was used to perform Western blotting (Figure 3B) using the antibodies that recognize
both the native and cleaved forms of SNAP25, yielding similar results to those shown in Figure 2A,
with significant cleavage of SNAP25 starting at a very low MOI (from 0.3 TU/cell). Lastly, in these
same neuronal samples, before RNA extraction and Western blotting, 75 mM KCl was first added to
the culture media and samples of the media were taken 30 min later to assess the extracellular levels of
CGRP using specific ELISA (Figure 3C). Results shown in Figure 3C indicate that the vector expressing
BoNT-A LC was able to induce a dose-dependent inhibition of CGRP secretion. In contrast, in neurons
infected with vectors expressing luciferase, or in control noninfected neurons, no inhibition of CGRP
release took place (data not shown). Significant inhibition of CGRP release can be observed starting
at a MOI of 1 TU/cell. Therefore, these results show a dose-dependent increase in RNA expression,
in SNAP25 cleavage, and in inhibition of CGRP release, clearly indicating that transgenic expression
of BoNT-A LC from HSV-1 amplicon vectors in cultured sensory neurons elicited both cleavage of
SNAP25 and inhibition of CGRP release.
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indicated in the text. The following day, culture samples were processed for qRT-PCR, Western blot and
ELISA. (A) qRT-PCR of RNA from cell xtracts showing a vector dose-dep ndent increase of BoNT-A
LC expression. Pr mers us d are escrib d in Material and Methods. Means d standar deviation
were calculated for each MOI. (B) Western blots of cell extracts, using antibodies specific for the cellular
prot in GAPDH or for SNAP25, showing the vector dose-dependent increase i SNAP25 cleavage.
(C) Inhibition of CGRP release expressed as the invers of the perce tage of inhibition of CGRP release
induced by the BoNT-A LC vector wit respect to that induced by the vector expressing Luc. A vector
dose-dependent increase in CGRP release inhibition can be observed. Means and standard deviation
were calculated for each MOI.
2.4. All BoNT LC Types Display Cleavage of Their Cognate SNARE Protein and Inhibition of CGRP Release
The next set of experiments was designed to extend the above results to other BoNT LC and to
comparatively assess their expression and activities in infected sensory neurons. Firstly, cultures of
embryonic rat sensory neurons were infected with vectors expressing the LC of BoNT-A, -B, -C, -D,
-E, -F, or Luc, at a MOI of 3 TU/cell. Western blots of cell extracts performed the next day show that
the cognate SNARE proteins targeted by the different BoNT LC were cleaved in all cases (Figure 4).
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Therefore, SNAP25 was cleaved by vectors expressing the LC of BoNT-A, -C and -E (lanes 2, 4 and
6), while VAMP2 was cleaved by vectors expressing the LC of BoNT-B, -D and -F (lanes 3, 5 and
7). As expected, BoNT-C LC also cleaved syntaxin (STX) in addition to SNAP25 (lane 4), being the
only BoNT able to cleave two different SNARE proteins [5,6]. BoNT-A, -C and -E cleave SNAP25
at different places, explaining the small differences in size of the cleaved products as compared to
noncleaved SNAP25. Since the cleavage fragments of VAMP2 and STX are rapidly degraded following
cleavage [46], these proteins are no longer visible in the Western blot.
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Figure 4. Each transgenic BoNT LC cleaves its cognate SNARE protein. Primary cultures of rat sensory
DRG neurons were infected at MOI of 3 TU/cell with vectors expressing the LC of BoNT-A, -B, -C,
-D, -E, -F or Luc, as control. The following day culture samples were processed for Western blot using
antibodies specific for each of the three SNARE proteins (SNAP25, VAMP2 and STX). It can be observed
in this figure that the LC of BoNT-A, -C, and -E cleave SNAP25 and that the cleaved products in each
case display a slightly different migration, corresponding to different SNAP25 cleavage sites targeted
by each of these three neurotoxins. Vectors expressing the LC of BoNT-B, -D and -F result in cleavage
of VAMP2, rendering this protein undetectable by the VAMP2-specific antibody. Similarly, STX is also
undetectable in extracts from neuronal cultures infected by the vector expressing BoNT-C. In the lanes
labelled Luc the positions on the blot of native STX, SNAP25 and VAMP2 can be observed.
In a second experiment, cultured rat embryonic DRG neurons were infected with vectors
expressing the LC of BoNT-A, -B, -C, -D, -E, -F, or Luc at increasing MOI (from 0.3 to 3.0 TU/cell).
On the following day, microphotographs of GFP autofluorescence were taken to confirm that all
cultures had been infected at comparable levels (data not shown). As in the experiment described in
Figure 3, cell samples were treated with KCl to induce CGRP secretion. Then neurons were harvested
for Western blots to assess cleavage f SNARE proteins. Results shown i Figure 5A indicate that
all BoNT LC were able to inhibit CGRP release in a vector dose-dependent manner, although they
did so with variable potencies. Thus, the vector expressing BoNT-F LC produced a greater inhibition
of CGRP release than those expressing BoNT-B or -D LC, which also cleave VAMP2. Indeed, at a
MOI of 1 TU/cell BoNT-F LC inhibits CGRP release as efficiently as BoNT-B LC at 3 TU/cell and is
more potent than BoNT-D LC at 3 TU/cell. Regarding the BoNTs that cleave SNAP25, no significative
differences were evident between BoNT-A, BoNT-C and BoNT-E LCs in inhibiting CGRP secretion.
It must be noted however that BoNT-C LC cleaves STX in addition to SNAP25, and this could also
contribute to inhibition of neurosecretion [5,6]. In mock-infected embryonic rat sensory neurons or
in neurons infected with a vector expressing Luc, no inhibition of CGRP release took place (data not
shown). It is noteworthy that inhibition of CGRP release can be detected in some cases in neurons
infected at MOI lower than 1 TU/cell, suggesting that a single infecting vector particle per cell was
able to synthesize enough neurotoxin for neurosecretion inhibition, thus highlighting the potency of
these vectors as a source of intracellular toxin.
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Figure 5. All transgenic BoNT LC types inhibit CGRP release from infected neurons. Primary cultures
of rat sensory neurons were infected at increasing MOI, from 0.1 to 3.0 TU/cell, with vectors expressing
the different toxins. The following day, culture samples were processed for ELISA and Western blots.
(A) Inhibition of CGRP release expressed as the inverse of the percentage of inhibition of CGRP
release induced by each BoNT LC vector with respect to that induced by the vector expressing Luc.
For each vector, a dose-dependent increase in CGRP release inhibition can be observed, although the
potency of inhibition by each vector varies. Statistical analysis was performed using the Student’s
t-test, *** corresponding to < 0.001 (GraphP d Prism v5). (B) Western blots of cell extracts using
antibodies specific for the cellular pr tein GAPDH or for STX, VAMP2 and the nati and cleaved
forms of SNAP25. For e ch vecto , a dose-dependent increase in the level of SNARE protein cleavage
can be observed.
By analyzing cleavage of the SNARE proteins (Figure 5B) at different MOI, it was found in all
experiments that levels of the native SNAP25, VAMP2, and STX proteins progressively decrease with
the infectious dos and the native forms of thes proteins are no longer visible in the gel at the highest
MOI. We then investigated whether a relationship could be established between potency of inhibition
of CGRP release and levels of cleavage of the SNARE proteins. As shown in Figure 5B, considering
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cleavage of SNAP25, the blot shows that BoNT-A LC cleaved significant amounts of SNAP25 even
at 0.3 TU/cell and at 3 TU/cell native SNAP25 is no more detectable, while with BoNT-E LC native
SNAP25 was still detectable even at 3 TU/cell. The effect of BoNT-C LC is harder to analyze due to the
small difference in molecular weight between the native and cleaved forms of SNAP25. Accordingly,
with BoNT-C LC expressing vectors we have used the antibody recognizing only the cleaved form.
It came out that detectable amounts of cleaved SNAP25 were observed at 1 TU/cell. Cleavage of
STX was also found at 1.0 TU/cell with BoNT-C LC expressing vector. Regarding the BoNTs that
cleave VAMP2, BoNT-B and -F LC displayed a similar behavior, with VAMP2 becoming undetectable
at MOI as low as 1 TU/cell, while cleavage of VAMP2 by vector expressing BoNT-D LC is much lower,
becoming clearly evident only at a MOI of 3 TU/cell. Taken together, these results indicate that the
level of inhibition of CGRP release and cleavage of SNARE proteins both increase with the dose of
the infecting vector, and suggest a reasonable correlation between both parameters. It is noteworthy
from Figure 5A,B that a significant proportion of CGRP is still released even under conditions where
SNARE proteins are no longer detectable. In these experiments, BoNT-F LC reproducibly appeared
as the most potent inhibitor of CGRP release when expressed from HSV-1-based amplicon vectors in
embryonic rat sensory neurons.
3. Discussion
Nonreplicative, nontoxic amplicon vectors derived from neurotropic HSV-1, expressing the LC
of botulinum neurotoxins, BoNT-A, -B, -C, -D, -E and -F, all of them driven by the strong HCMV
IE promoter, have been constructed and assessed. Results reported in this study indicate that these
vectors were able to infect embryonic and adult rat DRG neurons, respectively as primary cultures and
as organotypic cultures, and that the transgenic BoNT LCs were expressed in all cases, thereby cleaving
their cognate SNARE protein and significantly decreasing neurosecretion of CGRP in embryonic rat
sensory neurons. Boulis and coworkers previously described the use of adenovirus vectors to study
properties of the light chains of the related tetanus neurotoxin [18,19]. As far as we know however, our
study is the first to investigate and compare the effects of transgenic BoNT LC, following infection
from neurotropic HSV-1-based vectors, or from any other viral vector.
Native BoNT-A holotoxin, delivered as an extracellular protein, is currently being used both for
clinical and cosmetic applications and there is much interest in further understanding its molecular
effects in eukaryotic neurons and in comparing its biological properties to those of other BoNT
serotypes. Our approach, consisting in directly expressing transgenic BoNT LC in neurons, could be
very useful in this regard as it allows the study of effects of the harmless light chain in the absence of
the heavy chain, particularly as the native protein is extremely toxic and cannot be used by research
laboratories without specific authorization. In addition, variability between the different BoNTs could
be due at least in part to differences at the level of toxin binding and penetration, which relies on the
properties of the heavy chain. It should be noted however that exogenously administrated holotoxins
and vector-induced synthesis of transgenic LC could differ in several quantitative and qualitative
ways, including expression, concentration, localization, trafficking, solubility, and ubiquitin-mediated
degradation [47]. Indeed these differences could explain some discrepancies between our results and
those obtained using holotoxins [47]. Botulinum neurotoxins, both when secreted by bacteria through
natural infection or injected for clinical or cosmetic indications, attach to the synaptic membrane of
neurons and are internalized into endosomes. From there the protein is cleaved and the light chain
is released into the synaptic region, close to the SNARE exocytotic apparatus, where the toxins will
exert their endopeptidase activities, cleaving their cognate targets and disrupting neurosecretion and
neurotransmission [1–4]. In the case of the vector-induced transgenic expression used in our approach,
and although we have not performed in depth molecular studies, it can be assumed that the transgenes
are transcribed in the nucleus, and that the mRNA will be translated in the soma of the transduced
neurons. Since BoNTs are bacterial proteins, having no eukaryotic localization signals, they should
most likely disseminate homogenously within the whole neuron cytoplasm, without displaying any
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preferential localization to synaptic regions. Yet, the transgenic BoNT LC were able to efficiently cleave
their target proteins and to inhibit neurotransmitter release, suggesting that a significant fraction of
them were either able to reach the synaptic region to interact with their target or, alternatively, that the
toxins could bind and cleave their target proteins before they reach the synaptic region. More studies
using specific antibodies for the toxins are needed in order to address this point. If the BoNTs actually
bind the SNARE proteins only in the synaptic region, it should be possible to increase the fraction of
transduced neurotoxin localized to this region by introducing synaptic-region localizing signals to the
toxins, thereby improving their trafficking to the synaptic region and increasing their efficacy. This is
currently being done in our laboratory. These vectors could be very promising tools to study BoNT-LC
trafficking and physiology in neuronal cells.
The present data show clear significant biological effects induced by transgenic BoNT LCs
synthesized in neurons, as both cleavage of the corresponding SNARE proteins and inhibition of
neuropeptide release could be observed even at very low multiplicities of infection. Other studies
have already demonstrated a correlation between cleavage of SNARE proteins and inhibition of
neurotransmitter release following administration of BoNT holotoxins [48]. Remarkably, in our case,
cultured neurons infected at less than 1 TU/cell exhibit a significant inhibition of CGRP release,
pointing out the efficacy of these vectors. This likely results from the ability of HSV-1 to efficiently
penetrate and be retrogradely transported in sensory neurons, combined with the intrinsic properties
of amplicon vectors, which produces very high expression levels due to the reiterative structure of the
vector genome [20–22]. However, results presented in Figure 5 also show that some level of CGRP
release persisted even in conditions where the SNARE proteins are no longer detectable. Although we
have not directly addressed this point, it is likely that the residual release of CGRP could be explained
by the presence of undetectable amounts of native, non-cleaved SNARE proteins.
Our approach could be an efficient alternative to the supply of the native toxins in specific
future therapeutics approaches. Indeed, BoNT-A and BoNT-B are already approved for a variety of
indications, while other applications are presently in development [49]. However, direct administration
of BoNTs, although having represented a very important breakthrough in the treatment of some
pathologies, still displays important drawbacks and limitations, such as the need to regularly repeat
the treatment, since the half-life of the protein is limited, or the fact that in some cases, some resistance
could appear [50]. Our strategy could therefore become a preferred approach to induce continued
intracellular synthesis of the BoNT-LC, thereby resolving at least some of these limitations. Although in
the present study BoNT expression was driven by the transient HCMV promoter, thereby not allowing
long-term studies, the very large genomic capacity of HSV-1 vectors permits the introduction of viral
or cellular genetic elements able to confer long-term transgenic expression, as well as neuron-specific
promoters, or even inducible promoters, to drive transgene expression, thus allowing stable, selective,
or controllable, BoNT LC expression in different types of neurons. This could open new perspectives
both in the understanding of the basic biology of BoNT-LCs, as well as for therapeutic development.
4. Materials and Methods
4.1. Primary Cultures of Embryonic Rat Dorsal Root Ganglia (DRG) Neurons
Pregnant female adult Sprague-Dawley rats (250 g, E14–E18) were sacrificed in accordance with
the European Communities Council Directives 2010/63/UE on the use of laboratory animal and
care regulation in force in France (Ministry of Agriculture, Authorization Agreement No. A78-322-3,
18 December 2013 and B78-423-1, 28 July 2017). Embryonic rat DRG were dissected in a Petri dish
containing sterile ice-cold Hanks balanced salt solution containing 0.4% dextrose (HBSS-D). Sensory
neurons were dissociated in trypsin/EDTA solution and incubated 20–40 min at 37 ◦C, before being
seeded in poly-D-Lysine (0.1 mg/mL) coated microplates (Nunc 96 wells) at a density of 50.000 cell
per well in 100 µL of Neurobasal Sup Medium (Neurobasal medium, 5–10% inactivated fetal bovine
serum (iFBS), 2% B27, 2 mM L-glutamine, 50 U/mL streptomycin and penicillin, and 250 ng/mL NGF).
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After 45 min 200 µL of Neurobasal Sup Medium was added. Cells were cultured in an incubator (5%
CO2 at 37 ◦C). On the third day of culture, culture media were removed and replaced by 200 µL of
Neurobasal Sup Medium with the addition of the mitotic inhibitor cytosine arabinoside (10 µM) until
the fourth day. After 4 days of culture, media were removed and the vectors, diluted in 200 µL of fresh
culture medium, were added at the MOI indicated in the text.
4.2. Organotypic Cultures of Rat Adult DRG
Female adult rats (250 g) (Sprague-Dawley) were sacrificed in accordance with the European
Communities Council Directives 2010/63/UE on the use of laboratory animal and care regulation in
force in France (Ministry of Agriculture, Authorization Agreement No. A78-322-3, 18 December 2013
and B78-423-1, 28 July 2017). After death, a dorsal middle incision was performed to expose S3-L4
vertebrae. Supraspinous, interspinous, and yellow ligaments, were sectioned. A laminectomy was
then performed to expose the spinal cord and L4 to S2 DRG. S1 and L6 DRG were harvested separately
and immediately put into a M24 plate precoated with 15 to 20 µL of Matrigel (SIGMA, Saint Louis, MO,
USA) 30 min before plating ganglia. Neurobasal Medium supplemented with 5–10% iFBS was then
added to overlay the ganglia. Media were renewed every 2 days. After 3 days, once neurite outgrowth
allowed infection of internal neurons, a suspension of 2 × 106 vector particles was added directly to
the ganglia and left until the end of experimentation.
4.3. Construction and Titration of Nonreplicative HSV-1 Amplicon Vectors
4.3.1. Plasmids Containing the LC of BoNTs
A family of pUC57 plasmids carrying the sequences of the light chains of BoNT-A, -B, -C, -D,
-E, and –F, as described in GeneBank [accession numbers of BoNT-A LC: DL193752.1; BoNT-B LC:
KF878257.1; BoNT-C LC: X53751.1; BoNT-D LC: AB012112; BoNT-E LC: EF028403.1; BoNT-F LC:
GU213203.1] has been ordered (GenScript). An additional pUC57 plasmid, carrying the sequence of
GFP-BoNT-A LC fused protein was also constructed. Since the BoNT genes are of bacterial origin,
the sequences carried by the pUC57 plasmids were modified to take into account the codon usage
of mammalian cells, thus optimizing translation in these cells but without modifying the translated
product. In addition all these sequences were engineered to contain a NheI site at the 5′ end and a
NotI site at the 3′ end to facilitate subcloning into amplicon plasmids.
4.3.2. Generation of Amplicon Plasmids
A set of HSV-1 amplicon plasmids carrying the sequences of the BoNT LC, or firefly luciferase
as control, driven in all cases by the immediate-early promoter of human cytomegalovirus (HCMV)
enhancer/promoter, was constructed. For this, the pUC57 plasmids were digested by NheI/NotI
and the fragments carrying the neurotoxin coding regions were cloned into the NheI/NotI sites of
amplicon plasmid pA-EUA1 [51] thus generating the amplicon plasmids BoNT-A, -B, -C, -D, -E, and –F
respectively, as illustrated in Figure 1. It is noteworthy that these amplicon plasmids also express a GFP
reporter gene driven by the IE4/5 immediate-early promoter of HSV-1 [51]. In addition an amplicon
plasmid was constructed to express the GFP-BoNT-A LC fusion protein. This plasmid was constructed
by sub-cloning the GFP-BoNT-A LC fragment into the NheI/NotI sites of pA-SK, an amplicon plasmid
very similar to pA-EUA1, except that it does not contain the GFP transcription cassette [52].
4.3.3. Production and Titration of Amplicon Vector Particles
Amplicon vector stocks were prepared as already described, using the highly neuro-attenuated,
nonreplicative HSV-1LaL∆J virus as helper [52]. Briefly, 7B cells [53] were independently transfected
with 5 µg of each amplicon plasmid using Lipofectamine Plus (Thermofisher, Invitrogen, Carlsbad,
CA, USA). One day later, transfected cells were superinfected at a MOI of 0.3 plaque forming unit
(PFU) per cell, with HSV-1LaL∆J helper virus. When the cytopathic effect (CPE) was maximal,
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cells were collected by centrifugation, disrupted by three freeze/thaw cycles to release vector stocks,
and re-centrifuged at 1000× g for 10 min to pellet the cell debris. Helper and vector particles in the
supernatants were then titrated as already described [49]. Cells expressing fluorescent GFP were
scored at 24 h postinfection (pi) using an inverted fluorescence microscope (Olympus, Tokyo, Japan)
yielding transducing units (TU). Titers of helper virus particles are provided as plaque-forming units
(PFU) per millilitre, as already described [49]. Serial passages of the vector populations were then
carried out on 7B cells, thus increasing the TU/PFU ratio to 99/1 or higher.
4.3.4. Infection Procedure
After 4 days of culture of primary culture of rat embryonic DRG neurons, or once explanted DRG
displayed neurite outgrowth (usually after 3 days in culture), the culture medium was withdrawn
and replaced with a minimal amount of medium containing the vector suspension. After two hours
of contact, fresh medium was added to the wells and the cultures were kept at 37 ◦C in a 5% CO2
atmosphere until the end of the experiments.
4.3.5. qRT-PCR
At 24hpi culture media were removed and cells were resuspended into RLT buffer containing
10% β-mercaptoethanol. RNA was then extracted using Qiagen RNeasy MiniKit (Qiagen GmbH,
Hilden, Germany) and cDNA was obtained using SuperscriptIII (Thermofisher, Invitrogen, Carlsbad,
CA, USA), qRT-PCR was performed using GoTaq G2 Colorless Mix and using the oligonucleotides
shown in Table 1 (Eurogentech, Liege, Belgium). Results were normalized with respect to the cellular
house-keeping gene GAPDH.
Table 1. Oligonucleotides used in the qRT-PCR reactions.
Name of Oligonucleotide Sequence of Oligonucleotide
RT-BoNT-A F1 GCGCCGACATCATCCAGTTC
RT-BoNT-A R1 GTGTCCACCTCCAGGCTCTC
Rat.GAPDH-1049F GTGGACCTCATGGCCTACAT
Rat.GAPDH-1190R TGTGAGGGAGATGCTCAGTG
4.3.6. Western Blots (WB)
At 24hpi, culture medium was removed and cells were resuspended into RIPA lysis buffer
(Thermofisher, Rockford, IL, USA). After cell lysis, homogenates were centrifuged at 10,000 rpm
for 10 min at 4 ◦C. Cell lysates were resuspended into Laemmli buffer (Bio-Rad Laboratories Inc,
Hercules, CA, USA). After protein quantification, 50 µg of protein was used to perform electrophoresis
(Tris-HCl PAGE-Gel, Bio-Rad laboratories Inc, Hercules, CA, USA). Transfer of proteins was performed
using activated-methanol membrane (Immobilon FL Transfer Membrane, Merck Millipore, Tullagreen,
Carrigtwohill, County Cork, Ireland) at 4 ◦C during 1h30 with 0.35A. Blocking and antibody incubation
(shown in Table 2) were performed using the IBindTM Flex Western System SFL2000 (Thermofisher,
Invitrogen, Carlsbad, CA, USA). The intensity of each band was determined by pixel density integration
using LI-COR® Odyssey Western Blotting Kits.
4.3.7. ELISA
Primary cultures of embryonic rat DRG neurons were infected at increasing MOI, as indicated
in the text, with amplicon vectors expressing the different BoNT LC. At 24hpi, cultured neurons
were stimulated with 75 mM KCl to induce CGRP release [45]. Thirty minutes before and thirty
minutes following KCl treatment, 100 microliter aliquots were taken from the culture media and
assessed for the presence of CGRP by ELISA (using the CGRP ELISA kit from Spi Bio, ref N◦
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A05482, Montigny-le-Bretonneux, France, Statistical analysis was performed using the Student t
test, *** corresponding to p < 0.001 (GraphPad Prism v5, San Diego, CA, USA).
Table 2. Primary and secondary antibodies used in the Western blots.
Primary Antibodies Brand Reference Species
STX ABCAM ab3265 Rabbit
SNAP25 ABCAM ab66066 Rabbit
VAMP2 ABCAM ab3347 Rabbit
SNAP25 IPSEN Rabbit
GAPDH Millipore CB1001 Mouse
GFP Life technologies A6455 Rabbit
Secondary Antibodies Brand Reference Species
Mouse (800) Li-Cor 926-32210 Goat
Rabbit (680) Li-Cor 926-68071 Goat
Rabbit (800) Li-Cor 926-32211 Goat
4.4. Note on Biosafety and Biosecurity
There is currently significant concern about the potential misuse of vectors expressing toxins or
toxic proteins in general [54]. Accordingly, all genetic constructs used in this study were declared
as genetic modified organisms (GMO) expressing the LC of BoNTs to the French regulatory agency
(authorization file N◦ 3910) and the study was conducted in accordance to the safety and confinement
requirements established by the French regulatory authorities.
Although, as quoted in Introduction, Clostridium neurotoxins are amongst the most potent
biological neurotoxins, the use of HSV-1-derived vectors expressing BoNT LC under the control of
HCMV promoter appears to be safe for several reasons. (i) Many studies have demonstrated that
the use of isolated LC does not pose a threat since these proteolytic fragments do not cross cellular
membranes and are not capable of neuronal binding and uptake without the HC [18,19]. (ii) The
amplicon vectors used in this study are fully defective HSV-1-derived vectors, encoding no viral
lytic genes and inducing no destruction of the infected cells. These vectors are unable to replicate in
the absence of a helper virus that provides structural and replicative functions [20–22]. The helper
virus used in this study is itself defective [52] and can replicate only in cells, such as the 7B cells
used in this study, which complement in trans the essential functions that have been deleted from
the helper virus genome [53]. This prevents multiplication and spread of the vectors outside the
complementing cells. (iii) The HCMV promoter that drives expression of the BoNTs LC is well known
to be a strong and ubiquitous but transient promoter when expressed from HSV-1 gene transfer
platform [55], meaning that expression is completely silenced between 2 or 3 weeks postinfection,
both in in vitro and in vivo systems.
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